Celator Pharmaceuticals plans to price public sale of its equity units

Roth Capital Partners and National Securities are bookrunning managers

By Devika Patel

Knoxville, Tenn., Oct. 17 – Celator Pharmaceuticals Inc. will price a public offering of units with a 30-day greenshoe, according to a prospectus supplement filed Friday with the Securities and Exchange Commission.

The units will consist of one common share and one-tenth of a five-year warrant.

Roth Capital Partners and National Securities Corp. are the joint bookrunners.

Proceeds will be used for general corporate purposes, including clinical trials, research and development, general and administrative expenses, manufacturing and potential acquisitions.

The pharmaceutical company is based in Ewing, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.